AUTHOR INDEX

Volume 21, 1991

Abe, M., 1231
Abe, Y., 1529
Abitbol, A.A., 1321, 1621
Able, C.M., 1063
Abner, A.L., 331, 355
Abramson, D., 625
Adams, G.E., 387
Adelstein, S.J., 1541
Ahmad, K., 1275
Ahn, D.K., 709
Alexander, M., 1675
Alexander III, E., 591, 683, 737
Allain, Y.M., 369
Amdur, R.J., 651
Anderson, L.L., 483, 537
Anhalt, D.P., 831
Anscher, M.S., 941
Apuzzo, M.L.J., 715
Arai, Y., 1501
Araujo, C.M.M., 557
Arcangeli, G., 1569
Armstrong, J.G., 703, 1269
Aron, B.S., 415
Artwohl, J.E., 1235
Asbell, S.O., 925, 935, 1099
Ash, D.V., 1479
Ashford, R.F.U., 871
Auquier, A., 361
Averette, H.E., 1621
Awan, A., 1575

Bacelar, S.C., 557
Baillie, A., 1105
Ball, D., 459
Ballinger, W.E., 607
Bansal, P., 637
Baranowska-Kortylewicz, J., 1541
Barest, G., 37, 205, 217
Bataini, J.P., 615
Beach, J.L., 1053
Beck-Bornholdt, H.-P., 675
Beckett, M., 1677
Beckmann, M.W., 1235
Bedford, J.S., 1457
Begg, C.B., 537
Begnozzi, L., 1569
Beinfield, M., 293
Bell, R.S., 1595
Benassi, M., 1569
Bentel, G.C., 1045
Berkenstock, K.G., 955
Berman, R.M., 1541
Bhandare, N., 511
Bishop, J., 459
Blitzer, P., 183
Block, A.J., 651
Bohler, P.J., 423
Bolanis, N., 995
Bonner, R., 441
Bonnet, J., 749
Borger, F., 795
Born, A.M., 415
Borofski, A.M., 955
Bosl, G.J., 703
Bowen, J., 1005
Bowler, J., 387
Boyer, A.L., 501
Brabbins, D., 1019
Brada, M., 825
Brady, L.W., 955
Bragg, D.G., 841, 847
Brand, W.N., 1353
Brandon, A.H., 1621
Breneman, J.C., 1393
Brennan, M.F., 1485
Brenner, D.J., 819, 1403, 1415
Brenner, H., 169, 183
Brewster, L., 71, 137, 193, 253
Brezovich, I.A., 1073
Briot, E., 1107
Brock, W.A., 661
Brooks, M.T., 1501
Brown, A.P., 109, 147, 169, 205, 229
Brown, J.M., 1435
Brun, B., 325
Bryer, M.P., 1137
Buck, B.A., 737
Bull, C., 459
Buncher, C.R., 415
Bunn Jr., P.A., 869
Burgers, J.M.V., 1167
Burman, C., 123, 137, 169, 229, 243, 253
Burnel, W.M., 1241
Burton, M.A., 463
Buskirk, S.J., 729
Byhardt, R.W., 866

Calitchi, E., 325, 1173
Calton, C., 1595
Camel, H.M., 379, 885
Canary, P.C.V., 557
Cantor, A., 1509
Cantrell, R.W., 577
Caracciolo, F., 451
Carde, P., 447, 1167
Casale, C., 1569
Cassady, J.R., 831
Cassisi, N.J., 1607
Castelain, B., 369
Castro, J.R., 1653
Catton, C., 1595
Catton, C.N., 1115, 1291
Cellini, N., 451
Cha, C., 1393
Chafe, W.E., 899
Chan, A.S., 1241
Chaney, E.L., 475, 767, 1106
Chaplain, G., 369
Chasin, W.D., 563
Chavaudra, N., 661
Chen, G.T.Y., 779, 795, 1575
Cheng, C.-W., 683, 737
Cheng, E., 169, 183, 193, 205, 217, 229, 243, 253
Chin, R.B., 431
Chiru, P., 1575
Chiu-Tsao, S.-T., 483
Chu, J.C.H., 71, 147, 193, 229, 243, 253, 1303
Chui, C.-S., 37, 229
Cing, C.C., 1613
Clement, J.A., 637
Cleveland, R., 1393
Cohen, A.M., 1283, 1621
Cohen, D., 715
Coia, L.R., 109, 147, 169, 183, 205, 217, 549, 1303
Cole, S., 387
Coleman, J.L., 1675
Colistro, F., 1569
Come, S., 331
Constable, W.C., 577
Cooper, J.D., 637
Copeland, J.F., 1627
Cordon-Cordo, C., 805
Cormier, W.J., 1394
Corn, B.W., 1303
Cosset, J.M., 447, 661, 1107
Cox, J.D., 925, 935
Cox, L., 289, 347
Crommelin, M., 1297
Crook, J., 1173
Crowley, J., 869
Crucitti, F., 451
Culbert, H., 1575
Cummings, B.J., 1115, 1291, 1595
Cupps, R.E., 729
Curran, W.J., 1676

Dachowski, L.J., 441
Daly, N.J., 749
D'Angio, G.J., 1676
Danjoux, C.J.E., 1363
Das, I., 1203, 1627
Davis, L.W., 549
Davis, R.L., 709
Day Jr., T.G., 911
DeLaney, T.F., 441, 1493
Delanian, S., 615
Delannes, M., 749
Delclos, L., 1013
Denepoux, R., 369
De Neve, W., 1297
Denman, D.L., 415
Deutsch, M., 521
de Vathaire, F., 361
Dewhirst, M., 1377
de Wolf-Peters, Ch., 1167
Diamond, J.J., 1085
Dickof, P., 1106
Dillehay, L.E., 397
Dische, S., 871
Dixon, P., 1005
Dobelbower Jr., R.R., 451, 1033, 1145
Dobrowsky, W., 1291
Doggett, S.R.L., 935, 1099
Doornbos, J.F., 961
Doppke, K.P., 37, 91, 147, 183, 193, 229
Drzymala, R.E., 71, 193, 229, 253
du Bois, W., 1471
Dubray, B., 661
Duez, N., 1167
Durci, M.L., 629
Duval, P., 459

Eapen, L.J., 1363
Eckhauser, M., 1393
Egan, G., 463
Egger, M.J., 515
Eifel, P.J., 1013
Eklund, K.E., 1635
Elbrond, O., 723
Ellsworth, R., 625
Elson, H.R., 415
Emami, B., 109, 123, 147, 205, 217
English, W., 1311
Enker, W.E., 1283
Epperson, R.D., 37
Epstein, A.H., 1669
Epstein, B., 583
Esche, B.A., 1363
Ettinger, D.S., 1601
Evans, R.G., 1671

Fair, W.R., 537
Fairclough, D.L., 1501
Falkvoll, K.H., 989
Fass, D., 625, 703, 1269
Fayad, F., 1621
Fermont, D.C., 871
Feuilhade, F., 325
Fiedler, J.A., 1621
Fineberg, B., 311, 339
Fischer, D., 293
Fischer, J.J., 1337
Fishman, E.K., 1601
FitzGerald, T.J., 1203, 1627
Flam, M.S., 709
Fletcher, G.H., 319, 523
Flickinger, J.C., 1107
Foens, C.S., 961
Fontanesi, J., 1501
Foote, R.L., 868
Forcard, J.J., 369
Forman, J., 243
Fornasier, V.L., 1595
Fowble, B.L., 269, 279, 299
Fowler, J.F., 813, 1097, 1451
Fox, R.A., 463
Fox, S., 885
Frick, L.M., 729
Friedman, N., 1553
Fu, K.K., 1523
Fuks, Z., 169, 537, 549, 805, 1269
Fushiki, M., 1231

Gaffney, C., 1005
Galakatos, A.E., 379, 885

Galvin, J., 183, 205, 217
Garcia, D.M., 311, 379
Garton, G., 1019
Gaze, M.N., 1315
Geara, F., 661, 1517
Geard, C.R., 975
Gehring, M.A., 491
Gelman, R.S., 591
Gerber, R.L., 1327
Gershenson, D.M., 1013
Gibbons, S., 1019
Gibbs Jr., F.A., 1247
Gillette, E.L., 1241
Gilmour, H.M., 1315
Girinski, T.A., 447, 661, 1108
Glabbeke, M.V., 1167
Glatstein, E., 441, 469, 1493, 1669
Goffinet, D.R., 867
Goitein, M., 71, 91, 109, 123, 137, 229
Goldson, A.L., 1389
Goldwein, J.W., 1676
Gonzalez-Arias, S., 1321
Gooch Jr., A.W., 1057
Goodman, G.B., 1005
Goodman, M., 569
Goodman, R.L., 269, 279, 299, 1311
Goor, C., 1297
Goraczko, A., 789
Gospodarowicz, M.K., 863
Gottesman, R., 1107
Graham, J.E., 1041
Graham, M.V., 311
Graham-Pole, J., 1509
Grau, C., 723
Gray, B.N., 463
Gray, J.R., 347
Greenberg, J., 1493
Greenberger, J.S., 1203
Greven, K.M., 919
Griffin, T.W., 857
Grigsby, P.W., 375, 379, 885, 905
Grimaud, E., 361
Grosch, E.J., 871
Guedea, F., 1607
Guichard, M.E., 1535
Gutin, P.H., 601, 709
Guttenberger, R., 1195

Haffty, B.G., 293
Halberg, F.E., 1241
Hall, E.J., 819, 1399, 1403, 1415
Hallahan, D.E., 1677
Haller, D.G., 1137
Halpern, H.J., 779, 1575
Halverson, K.J., 1327
Ham, B., 601
Han, I., 1275
Han, S., 1275
Hanks, G.E., 925, 935, 1085, 1099, 1145, 1303
Hanno, P.M., 1311
Harari, P.M., 831
Harms, W.B., 37, 71, 183
Harrington, F.S., 469
Harris, J.R., 331, 355, 529
Harrison, L.B., 703, 867, 1269, 1283, 1485
Hauer, C., 1393
Haulk, T., 1601
Hayat, M., 447
Hayes, D., 331
Hayes, F.A., 1501
Hazuka, M.B., 869
Heare, T.C., 1509
Heilbrun, M.P., 1247
Heimburger, D.K., 983
Hendrickson, F.R., 1041
Henry-Amar, M., 447
Herbert, S.H., 919
Herman, T.S., 969
Herpst, J., 1601
Herskovic, A., 1275
Hewrbert, S.H., 919
Hicks, J.E., 1493
Hilaris, B.S., 537, 1485
Hishikawa, Y., 1133
Hogan, P.E., 919
Hogstrom, K.R., 501, 695, 1063
Holt, J.A., 1235, 1275
Holupka, E.J., 683
Hopewell, J.W., 1441
Hopkins, R.E., 969
Hordijk, G.J., 1179
Houdek, P.V., 1321, 1621
Hricak, H., 1089
Huang, Y., 1415, 1613
Hunt, M., 183, 193
Hunter, N., 1195
Hussey, D.H., 961
Hwang, C.C., 1303
Hynynen, K.H., 831

Iwai, H., 1231

Janjan, N.A., 1343
Jenkin, D., 863
Johnson, C.R., 563
Johnson, P.M., 1353
Jones, B., 1108
Jose, B., 911
Jozsef, G., 949
Julien, M., 325
Jung, G.M., 369

Kagan, A.R., 1373
Kahn, J., 1529
Kallinowski, F., 667
Kallman, R.F., 1394
Kamikonya, N., 1133
Kao, M.-S., 379, 885
Karmody, C.S., 563
Kase, K., 1203, 1627
Kassis, A.I., 1541
Kawamoto, S., 1107
Keane, T.J., 1115, 1291
Kenton, L.A., 1529
Kessler, M.L., 1653
Kier, A.B., 415
Kim, K., 1033
Kinne, D., 289
Kinsella, T.J., 491, 859
Klein, E., 339
Klein, J.L., 1601
Klemp, P.F.B., 463
Knauf, D.G., 651
Koechlin, M., 369
Kohn, M.L., 1057
Komaki, R., 629
Konski, A.A., 1033
Kooy, H., 591, 683
Koprowski, C.D., 955
Korb, L.J., 577
Kotoura, Y., 1221
Kovalic, J.J., 905
Krall, J.M., 925, 1099, 1145
Kraut, M., 1275
Krippner, K.E., 37, 169
Kris, M.G., 1269
Kubsad, S.S., 491
Kufe, D., 1677
Kullander, S., 1235
Kun, L.E., 1501
Kurisu, K., 1133
Kuske, R., 193, 311, 339
Kutcher, G.J., 123, 137, 147, 169, 805
Kutcher, J.G., 91, 205
Kuten, A., 379

Ladyka, C., 1106
Lagrange, J.L., 369
Lai, P.P., 925
Laidlaw, C., 459
Lam, K.N., 1523
Lamb, S., 601
Lamborn, K., 601
Lampert, M.H., 1493
Lanciano, R.M., 919
Lange, C.S., 1385
Langholz, B., 715, 949
Langmuir, V., 795
Langston, M.Y., 397
Lapointe, C., 1105
Larson, D.A., 601
LaRue, S.M., 1241
Lattin, P., 1275
Lawrence, T.S., 983
Lawton, C.A., 9354
Le, M., 361
Leahy, J.M., 1676
Leavitt, D.D., 515, 1247
Le Bourgeois, J.-P., 325, 1173, 1517
Lee, D.-J., 583
Lee, M.S., 1041
Legorreta, R.A., 415
Leibel, S.A., 537, 549, 601, 805, 1269
Leichner, P.K., 1601
Leininger, S., 1033
Lemmon, M.J., 1435
Lesiak, J., 789
Lespinasse, F., 1535
Leung, T.C., 1327
Levin, V.A., 601, 709
Levine, P.A., 577
Levitt, S.H., 523
Lewandowski, B.J., 1363
Lewin, A.A., 1321, 1621
Lewis Jr., G.C., 415
Lichter, A.S., 853
Lieskovsky, G., 949
Lightfoot, D.A., 955
Lindberg, R.D., 911
Lindstrom, M.J., 813
Ling, C.C., 483, 805, 1613
Lingos, T.I., 355
Lipsett, J.A., 529
Littman, P.S., 1676
Lockett, M.A., 885, 905
Loeffler, J.S., 591, 683, 737
Lorimore, S.A., 387
LoSasso, T., 91, 217, 253
Lovecchio, J., 1107
Lovisolo, G., 1569
Low, N., 779, 1575
Lucas, G.L., 715
Luk, K.H., 529
Lundbeck, F., 1211
Luts, A., 1211
Luxton, G., 715, 949
Luzi, S., 451
Lybeert, M.M., 1297
Lyman, J., 109
Lyng, H., 423

MacDougall, R.H., 1315
Mackie, T.R., 491
Macklis, R.M., 1187
Mah, K., 1257
Maher, E.J., 871
Maitz, A.H., 1107
Makepeace, A.R., 871
Makrigiorgos, G.M., 1541
Malaise, E.P., 661
Malissard, L., 369
Malkasian, G., 1019
Manaster, B.J., 1643
Mannarino, E.G., 683
Mannarino, E.G., 737
Manolis, J.M., 169, 193, 205, 217, 229, 243, 253
Maran, A.G.D., 1315
Marcial, V.A., 549
Marcial-Vega, V.A., 1321
Marcus Jr., R.B., 607, 866, 1157, 1509
Marin, L.A., 397
Markoe, A.M., 1621
Marks, G., 1127
Marks, L.B., 1377
Martel, M.K., 819
Martijn, H., 1297
Martin, J.L., 1053
Martinez, A., 1019
Masko, G., 563
Masterson, M.E., 37
Matthews, J., 217, 243, 459
Mazeron, J.-J., 325, 865, 1173, 1517
McCarty, P.J., 899
McCormick, B., 193, 289, 347, 625
McCullough, W.M., 607
McDermot, R.S., 1363
McKhann, C., 293
McNeely, L.K., 515
McNeese, M.D., 319, 1063
Meerwaldt, J.H., 1167
Mehta, M.P., 491
Meigooni, A.S., 1337
Mendenhall, N.P., 1157, 1509
Mendenhall, W.M., 651, 868, 899, 1607
Mendiondo, O.A., 1053
Menon, K., 969

Meredith, R.F., 1073
Meyer, W.H., 1501
Milas, L., 1195
Miller, R.W., 469
Million, R.R., 607, 651, 868, 899, 1157, 1509, 1607
Mills, M.D., 1063
Min, W.S., 1553
Mina, L.L., 463
Minsky, B.D., 1283
Mitchell, J.B., 1553
Mittal, B.B., 1353
Miura, T., 1133
Moeller, J.H., 1247
Mohan, R., 37, 71, 91, 137, 147, 169, 183, 243, 805
Mohiuddin, M., 549, 1027, 1127
Moller, K., 723
Monconduit, M., 1167
Monge, O.R., 423
Montague, E.D., 319
Montana, G.S., 1045
Montemaggi, P., 451
Morgan, L.S., 899
Morganti, A.G., 451
Morton, J., 1337
Mountain, C.F., 629
Mouriesse, H., 361
Munzenrider, J.E., 91, 109, 147, 183, 193, 229
Murray, K., 637
Myles, J.L., 1033
Myrianthopoulos, L.C., 779, 1575

Nair, B.D., 1363
Nath, R., 995, 1337
Neal, C.R., 651
Nedzi, L.A., 591, 683
Neisler, J., 1033
Neuringer, L.J., 667
Ngan, S., 459
Nguyen, T.D., 369
Nielsen, O.S., 1595
Nishimoto, S.-I., 1231
Nolan, J., 387
Nori, D., 229
Norman, A., 1373
Noyes, D., 1145
Nyerick, C.E., 501

Obuz, V., 1553
Ochran, T.G., 501
O'Connor, T.P., 1393
O'Donoghue, J.A., 1587
Oka, M., 1221
Okunieff, P., 667
Oltikar, A., 1187
Order, S.E., 1601, 1676
Orton, C., 1275, 1425
Osborn, A.G., 841
O'Sullivan, B., 1115, 1291, 1595
Oswald, M.J., 319, 629
Otmezguine, Y., 325, 1173
Oubaha, L., 1553
Oussoren, Y., 1211
Ovadia, J., 469
Overgaard, J., 723
Overgaard, M., 723
Owens, J., 1145

Packer, R.J., 1676
Paine, C.H., 1479
Pajak, T.E., 637
Paliwal, B.R., 491
Panis, X., 369
Paradelo, J.C., 637
Pareek, P.N., 1073
Paris, K.J., 911
Park, C.H., 1553
Park, M., 1393
Parliament, M.B., 1363
Parsons, J.T., 868, 1607
Pavlovitch, J.-M., 325, 1517
Payne, D.G., 863
Pellae-Cosset, B., 447
Pellet, J.B., 1327
Perez, C.A., 311, 339, 375, 379, 885, 905, 925, 935, 1099
Peschel, R., 995
Peters, L.J., 1013
Petrovich, Z., 715, 949
Petti, P., 1653
Pezner, R.D., 529
Pfister, D.G., 703
Phibbs, G., 1033
Phillips, R., 1041
Phillips, T.L., 601, 709, 865, 1241
Photon Treatment Collaborative Working Group, 79
Photon Treatment Planning Collaborative Working Group, 3, 9, 25, 59, 165
Pickles, T., 1005
Piedbois, P., 325, 1517
Pierce, J.H., 1203
Pierce, L.J., 1311
Pierce, M.C., 1353
Pierquin, B., 325, 865, 1173
Pilepich, M.V., 243, 253, 925, 935, 1099
Pinto, L.H.J., 557
Pisciotta, V., 1621
Pisciotti, V., 1321
Pitluck, S., 1653
Podratz, K., 1019
Pomeroy, M., 1005
Ponvert, D., 615
Powers, B.E., 1241
Prados, M.D., 601, 709
Prosnitz, L.R., 941
Purdy, J.A., 1, 147, 217, 243
Puthawala, A., 868

Quashie, D., 397

Rademaker, A.W., 1353
Rao, B.N., 1501
Rathelot, P., 369
Raubitschek, A.A., 469
Ravasz, L.A., 1179
Rayner, A.A., 1241
Recht, A., 331, 355, 529
Reddy, S., 1041
Reisinger, S.A., 1027
Rheaume, D., 1005
Rhoton Jr., A.L., 607
Ribot, J.G., 1297
Roach III, M., 1675
Roberts, T.J., 583
Rodriguez, R., 857
Roemer, R.B., 831
Rofstad, E.K., 423
Romsdahl, M.A., 319
Rorke, L.B., 1676
Rosato, E.F., 1137
Rosen, P.P., 289
Rosenberg, I., 779, 795, 1575
Rosenberg, S.A., 1493
Rosenman, J.G., 767, 1105
Rosenstein, M.M., 1269
Rotman, M., 1385
Roy, J.N., 483
Rozan, R., 369
Rubin, P., 267, 535, 883, 925, 935, 1099, 1113, 1397
Rush, S., 1107
Russell, A.H., 637
Russo, A., 441
Ryan, T.P., 403

Sabatier, J., 749
Sailer, S.L., 767, 1105
Salazar, O.M., 645
Sallan, S.E., 1187
Salter, M.M., 1073
Santucci, M.A., 1203
Sapozink, M.D., 715
Sarrazin, D., 361
Sasai, K., 1231
Sathiaseelan, V., 1353
Saunders, M.I., 871
Sause, W.T., 925, 935, 1099, 1145
Sawyer, T., 1033
Saxena, V.S., 1041
Scharl, A., 1235
Schell, M.C., 1241, 1613
Scher, H.I., 1269
Schild, S.E., 729
Schmidt-Ullrich, R.K., 563
Schneider, D., 795
Schray, M., 1019
Schultz, D.J., 269, 279, 299
Schuster, R., 339
Schut, L., 1676
Schwade, J.G., 1321, 1621
Schwaibold, F., 299
Scott, C.B., 549
Selim, H.M., 637
Serago, C.F., 1321, 1621
Sessions, R.B., 703
Sevin, B.-U., 1621
Seyedsadr, M., 1275, 1425
Shah, J.P., 703
Shank, B., 109, 147, 217, 253, 1269
Sharma, S.C., 511
Shehata, W.M., 1394
Sherman, M.L., 1677
Sherouse, G.W., 475, 767, 1105
Shetty, M.R., 530
Shewach, D.S., 983
Shibamoto, Y., 1221, 1231
Shimm, D.S., 831
Shin, H.K., 1393
Shipley, W.U., 935
Shiu, A.S., 695
Shiu, M.H., 1485
Siddon, R.L., 683
Sigurdson, E., 1283
Silver, B., 331, 355
Silver, P., 601
Silverman, S., 637
Simon, J.-M., 1173
Simpson, J.R., 147, 169, 183, 229, 243, 379
Sizoo, W., 1167
Skinner, D.G., 949
Slawson, R.G., 645
Slessinger, E.D., 37
Smaniotto, D., 451
Smith, A.R., 1
Smith, C.E., 397
Smith, P., 441
Sneed, P.K., 601
Snippe, K., 1179
Solin, L.J., 109, 147, 193, 229, 243, 253, 269, 279, 299, 1137
Somers, R., 1167
Somnay, A., 1425
Song, C.W., 1553
Sontag, M.R., 37, 91, 183, 193
Sougawa, M., 1561
Souhami, L., 557
Spanos Jr., W.J., 911
Spaulding, C.A., 577
Spelbring, D., 1575
Sperduto, P.W., 441
Spiro, R.H., 703
Stafford, P.M., 1303
Stanhope, R., 1019
Staples, J.J., 961
Staros, E.B., 1027
Stauffer, P.R., 431
Stea, B., 831
Steinfeld, A.D., 1085
Stewart, F.A., 1211
Stewart, J.R., 515
Stillwagon, G.B., 1601
Stinson, S.F., 1493
Stratford, I.J., 387
Stringer, S.P., 1607
Strom, E.A., 319
Strong, E.W., 703
Sugimoto, M., 1221
Suit, H.D., 1399, 1471
Sundararaman, S., 415
Sutton, L.N., 1676
Suyama, S., 1231
Svensson, G.K., 737
Syed, A.M.N., 868
Szymczyk, W., 789

Taghian, A., 361, 1535
Takach Jr., G.A., 1247
Takahashi, M., 1221, 1231
Takahashi, S., 1221
Taniguchi, M., 1133
Tatsuzaki, H., 757
Taylor Jr., B.W., 1157
Teicher, B.A., 969
Tepper, J.E., 243, 253, 767, 1105, 1145
Terhaard, C.H.J., 1179
Terrier, P., 361
Thames, H.D., 1195
The Gastrointestinal Tumor Study Group, 1151

Thomas, G., 441
Thomas, J., 1167
Thompson, E., 1501
Thompson, W.M., 1367
Thomson, J., 1145
Tishler, R.B., 975
Tobin, R.L., 1127
Tremoulet, M., 749
Trenkner, S., 1367
Trott, K.R., 1108
Tsai, J.-S., 737
Tubiana, M., 361, 447
Tuchais, C., 369
Tucker, S.L., 1392

Uckun, F.M., 1553
Urano, M., 667, 1529, 1561
Urdaneta, N., 995
Urie, M.M., 37, 71, 91, 147, 169, 205, 229, 243, 253, 757

van de Geijn, J., 469
van den Aardweg, G.J.M.J., 1441
Van den Abbeele, A.D., 1541
van der Tweel, I., 1179
Van Dyk, J., 1257
Vanuytsel, L., 825
Vaupel, P., 667
Venzon, D., 1493
Vernimmen, F., 1005
Vicini, F.A., 331, 355
Vigliotti, A.P., 961
Vijayakumar, S., 779, 795, 1575
Vikram, B., 169
Virudachalam, R., 795
Virudachalam, S., 1677
Vitu, L., 1107
Vriesendorp, H.M., 1676

Waddick, K., 1553
Wallace, R.E., 37, 169
Wallner, K.E., 483, 537
Wang, C.C., 569, 865, 866, 1095
Wara, W.M., 601, 709
Wazer, D.E., 563
Weaver, K.A., 601
Weeks, K.J., 1045
Weichselbaum, R.R., 1575, 1677
Wein, A.J., 1311
Weiner, S., 1019
Weinhous, M.S., 1327
Weisen, S., 703
Weiss, K., 1393
Wen, B.-C., 961
Weppelman, B., 1073
Wessler, T., 1394
Wesson, M., 109
Wharton, J.T., 1013
White, D.E., 1493
White, M.L., 415
Whitmore, W.F., 537
Whittington, R., 1137, 1311
Willet, C.G., 1529
Williams, J.R., 1635
Williamson, J., 885
Wilson, C.B., 709
Wilson, J.A., 1315
Wilson, J.F., 1343
Wolkov, H.B., 1145
Wollin, M., 1373, 1392
Won, M., 935
Wong, C.S., 1115, 1291
Wong, J.W., 37, 91, 205, 1327
Wong, R., 1613
Wright, E.G., 387
Wu, A., 1107
Wu, X., 1621

Yahalom, J., 205, 289, 347
Yamada, S., 1195
Yamamuro, T., 1221
Yang, J.C., 1493
Yee, G.J., 645
Yordan, E.L., 1041
Yorke, E.D., 1613
Young, L., 339
Yukawa, Y., 1231

Zajac, A.J., 1057
Zellmer, D.L., 1343
Ziegler, J.C., 955
Zuks, Z., 243

SUBJECT INDEX

Volume 21, 1991

A

Abdominal failure, 1019
Aberrations, Chromosomal, 1457
Abutment dosimetry, 1063
Accelerated hyperfractionationradiotherapy, 569
Accelerated hyperfractionation, 1275
Accelerated repopulation, 1529
Accelerator, 789
Accelerators, Linear, 501
Accuracy, Algorithm, 37
Acute and late radiation reaction, 1441
Adenocarcinoma of the pancreas, 1137
Adenocarcinoma, 369
Adenoma, Pituitary, 607
Adenosine nucleoside triphosphate, 667
Adjuvant irradiation, 1019
Adjuvant therapy, 1137
Afterloading dome cylinder, 511
Afterloading, 1053, 1479
  High dose rate, 1057
  Remote, 1425
AIDS, 1517
Algorithm accuracy, 37
Alpha-beta ratio, 1529
Altered fractionation, 563, 1269
Anal cancer, 1337
Anal carcinoma, 1385
Analysis
  Dose-volume, 1343
  Flow cytometric DNA content, 1033
  Image, 1635
  Multivariate, 549
  Photon beam, 91
  Uncertainty, 91
Anti-CEA, 1601
Antibodies, 1601
Apical lung cancer, 651
Applicator
  Fletcher, 995
  Fletcher-Suit-Delclos, 1045
  Henschke, 995
  Plastic, 1045
  Ring, 1621
  Uterine-vaginal, 511
Arc therapy, 749
Assay, Hybrid spheroid, 1385
Auger-electron emitters, 1541
Autoradiography, Quantitative, 1635

B

B-lineage lymphopoiesis, 1553
B-lymphocyte ontogeny, 1553
Beam's eye view, 253, 779, 1575
Beam
  Electron, 1063, 1627
  External, 955
  Spoiler, 1627
Biliary tract neoplasms, 1601
Biodistribution, 1541
Biologically targeted radiotherapy, 1587
Biopsy, 1643
Bioreductive drugs, 387
Bladder, Mouse, 1211
Bone graft, 1221
Bone marrow rescue, 1587
Bone neoplasms, 1509
Bone tumor, 1221
Bone, 1613
Bone-tissue interface, 695
Brachutherapy, 1053
Brachytherapy, 375, 379, 431, 451, 537,625, 715, 911, 995, 1045, 1057,1173, 1283, 1403, 1415, 1479,1485, 1613, 1621
  Gynecological, 511
  HDR, 1425
  Interstitial, 601
  Intraluminal, 1133
  LDR, 1425
  Stereotactic, 715
Brain neoplasm, 715
Brain tumors, 819
Brain, 637
Breast cancer, 193
Breast recurrence, 269
Breast, 1343
  Cancer, 293, 293, 311, 325, 331, 339,347, 355, 361, 441, 1073
  Carcinoma, 279, 1173
  Conservation therapy, 289
  Conservation, 279
  Invasive ductal carcinoma, 423
  Locoregionally advanced cancer, 319
  Recurrence, 269
Bromodeoxyuridine, 709, 975
c-jun protooncogene, 1677

C

Calculations
  Complication probability, 137
  Dose, 25, 37
Calibration, Source, 1057
Cancer staging, 1089
Cancer(s), Uterine, 995
Cancer, 403
  Anal, 1337
  Apical lung, 651
  Breast, 193, 293, 293, 311, 325, 331,339, 347, 355, 361, 441, 1073
  Cervical, 375, 975
  Cervix, 229
  Colon, 1151
  Early laryngeal, 1179
  Endometrial, 919, 1019, 1027
  Epidermoid anal, 1115
  Esophageal, 1133
  Head and neck, 557, 813
  Liver, 463
  Locoregionally advanced breast, 319
  Lung, 217, 645, 779, 1275
  Non-small cell lung, 779
  Ovarian, 1013
  Pancreas 451
  Pancreatic, 1145
  Pituitary, 1311
  Prostate, 243, 935, 941, 949, 1099,1311
  Rectal, 1337
  Rectum and/or sigmoid, 1297
  Recurrent lung, 645
  Small cell lung, 459, 645
  Small-cell lung, 1269
  Spontaneous, 415
  Unresectable head and neck, 703
  Unresectable rectal, 1283
  Uterine cervical, 905
Canines, 415
Carcinogeneis, 1343
Carcinoma(s)
  Endometrial, 1033
  Hypopharyngeal, 767
Carcinoma
  Anus, 1385
  Breast, 279, 1173
  Cervix, 1089, 1415, 1425
  Colorectal, 983
  Endometrial, 379
  Endometrium, 1089
  Fixed rectal, 1127
  Glottic, 583
  Head and neck, 549, 563
  In-situ duct, 289
  In-situ of the cervix, 375
  Invasive ductal breast, 423
  Laryngeal, 767
  Larynx, 183
  Mammary, 1569
  Nasopharyngeal, 723
  Non-small cell lung, 629
  Oral tongue squamous cell, 577
  Oropharynx, 557
  Prostate, 537, 925, 955
  Rectal, 253, 1127
  Recurrent rectal, 1291
  Squamous cell, 563, 661
  Subglottic, 1607
  Vagina, 1041
Cell cycle redistribution, 397
Cell loss, 989
Cell(s)
  Hypoxic, 387
  Lymphoid precursor, 1553
  Mammalian, 1457
Cell
  Hematopoietic stem, 1203
  Stromal, 1203
Cervical cancer, 375, 975
Cervix, 911
  Cancer, 229
  Carcinoma in-situ, 375
  Carcinoma, 1089, 1415, 1425
Chair, 469
Chemo-radiation therapy, 1385
Chemosensitized radiation therapy, 1137
Chemotherapy, 331, 355, 703, 1157
  Concomitant with irradiation, 1269
  PCV, 709
Chiasmal gliomas, 615
Chromosomal aberrations, 1457
Clamping, 675
Clearance, 1235
Clinical results, 1385
Clonogens, 661
Cobalt-60, 625
Cochlea, 723
Colon cancer, 1151
Colorectal carcinoma, 983
Combination chemo-radiotherapy, 1167
Combination therapy, 1151
Combined effects, 1523
Combined modalities, 651
Combined modality therapy, 899, 1493
Combined modality treatment, 1509
Combined radiation and hyperthermia,1561
Combined radiosensitizers, 1535
Comparative treatment planning, 757

Comparison, 767
Complication probability calculations,137
Complications of treatment, 1157
Complications, 339, 355, 591, 885, 911,919, 1005, 1179, 1451
Radiation, 1471
Computed tomography, 193
Computer graphics, 9
Computer, 1635
Computer-controlled radiation therapy,1247
Computer, Graphics, 9
Computerized tomography (CT), 1045
Computerized treatment planning, 71
Concomitant chemotherapy andirradiation, 1269
Concomitant infusion, 1385
Conformal, 805
Conformational radiotherapy, 1575
Conservative surgery and radiotherapy,331
Conservative surgery, 293, 355
Consumptive coagulopathy, 729
Control probability, Tumor, 147
Control
Local, 805
Local-regional, 549
Locoregional, 1179
Correction factors, 1257
Corrections
Inhomogeneity, 59
Tissue inhomogeneity, 183
Cosmesis, 331, 339
Cosmetic results, 347
Cross-line data, 1479
CT-based implant planning, 483
CXervix, Neoplasms, 899
Cystometry, 1211
Cytogenetics, 1457

D

Daily treatment variation, 1327
Damage
DNA, 983
Potentially lethal, 1457
Radiation, 1211
Sublethal, 1457
Definitive breast irradiation, 279
Definitive radiotherapy, 1173
Delto volume, 59
Density, Vascular, 423
Design, New, 511
Disease
Hodgkin's, 205, 447, 1157
Display
Three-dimensional, 9, 79
Distant metastases, 805
Distant metastasis, 549
Distribution, Temperature, 423
DNA
Damage, 983
Repair, 983
Dose calculations, 25, 37
Dose computation, 683
Dose distribution
Improved, 1471
Three-dimensional, 767
Dose fractionation, Mathematicalmodels, 1441
Dose optimization, 885
Dose rate, 1173, 1403
High, 1621
Dose, 1005
Dose-volume analusis, 1343
Dose-volume histogram, 147, 515, 1575
Dose-volume histograms, 3, 71, 253,591, 683, 1303
Dose-volume, Histograms, 71
Dose
Calculations, 25, 37
Lung, 1257
Nominal standard, 1373
Radiation therapy, 1501
Radiation, 1471
Surface, 1627
Targer absorbed, 1257
Dosimetry systems, 1479
Dosimetry, 795, 995, 1063, 1343, 1541
Abutment, 1063
Electron, 501
Thermoluminescent, 1337
Duct carcinoma in-situ, 289
Duodenum, 1241

E

Early laryngeal cancer, 1179
Early, 1523
Effect
Tumor bed, 667, 1435
Effective path length, 59
Effects
Combined, 1523
Late, 1187
Ototoxic, 723
Pulmonary, 355
Treatment, 1493
Volume, 109
Electron dosimetry, 501
Electron
Arc therapy, 515
Backscatter factor, 695
Beam, 695, 1063, 1337, 1627
Cones, 501
Dosimetry, 501
Field lens block, 795
Ellipsoidal dome, 511
Endometrial cancer, 919, 1019, 1027
Endometrial carcinoma, 379, 1089
Endometrial carcinomas, 1033
Enhanced survival, 709
Enterohepatic circulation, 1235
Epidemic Kaposi's sarcoma, 1517
Epidermoid anal cancer, 1115
Esophageal cancer, 1133
Esophagus, 1303
Evaluation, Treatment planning, 137
Ewing's sarcoma, 1501, 1509
External beam radiation therapy, 961
External beam, 955
External photon treatment planning, 37

F

5-fluorodeoxyuridine, 983
5-fluorouracil, 1115, 1291, 1385
5-iodo-2'-deoxyuridine, 1541
5FU, 1385
^{14}C-misonidazole, 1435
Facility structure, 1085
Factor
Electron backscatter, 695
Output, 789
Therapeutic gain, 1561
Factors
Prognostic, 299, 629, 1179
Failure, Abdominal, 1019
FdUrd, 983
Female urethra, 961
Ferromagnetic seed, 431
Field size, 1595
Fields, Tangential, 1073
Finite element method, 431
Fixed rectal carcinoma, 1127
Fletcher applicator, 995
Fletcher-Suit-Delclos applicator, 1045
Flow cytometric DNA content analysis,1033
Fluosol-DA, 969
Fractionated irradiation, 749, 1231
Fractionation, 675, 813, 819, 1451, 1529
Altered, 563, 1269
Radiation, 1377
Time-dose, 925
Twice-daily, 1013
FSa-II tumor, 1529
Function, Limb, 1493

G

Gamma-50, 1471
Generalized linear models, 813
Glioblastoma multiforme, 601, 709
Glioblastoma, 397
Glioma(s)
Chiasmal, 615
Malignant, 715
Glioma, Malignant, 601
Gliomas, Malignant, 709
Glottic carcinoma, 583
Grade, Low, 1167
Graphics, Interactive computer, 79
Gynecological brachytherapy, 511

H

Halogenated pyrimidines, 709, 975
HDR brachytherapy, 1425
Head and neck
Cancer, 557, 813
Carcinoma, 549, 563
Hearing, 723
Heavy, 347
Hemangiomas, 729
Hematopoietic stem cell, 1203
Hematoporphyrin derivative, 441
Hemoglobin, 969
Henschke applicator, 995
Hepatic irradiation, 1151
High dose rate afterloading, 1057
High dose rate, 1415, 1621
Histogram
Dose-volume, 147, 515, 1575
Histograms
Dose-volume, 71, 253, 591, 683, 1303
Histology, Quatitative, 989
Hodgkin's disease, 205, 447, 1157
Human melanoma xenograft, 989
Human tumor xenografts, 1535
Hybrid spheroid assay, 1385
Hydralazine, 1435
Hyperfractionation, 557, 1509
Accelerated, 1275
Hyperthermia, 403, 415, 423, 831, 989,1353, 1561, 1569
Interstitial, 431
Hypopharyngeal carcinomas, 767
Hypoxia, 675
Tumor, 969, 1435
Hypoxic cell radiosensitizer, 1231
Hypoxic cells, 387

I

I-125, 1613
I-125 implants, 483
Image analysis, 1635

Image registration, 1653
Imaging, 9
MR, 1089
Multimodality, 1653
On-line radiotherapy, 1327
Implant(s), Prostate, 483
Implant, 955
Implantation, Iodine-125, 537
Implants
I-125, 483
Transperineal, 483
Impotence, 1311
Improved dose distribution, 1471
Ingestible, 1353
Inhomogeneity corrections, 59, 1257
Inhomogeneity, 591
Inhomogeneous phantom, 695
Inner ear, 723
Instrumentation, 469
Interactive computer graphics, 79
Internal shielding, 1337
Interstitial brachytherapy, 601
Interstitial hyperthermia, 431
Interstitial radiation therapy, 451, 961
Interstitial therapy, 1479
Interstitial, 403
Irradiation, 1485
Therapy, 1479
Intracavitary irradiation, 995
Intracavitary therapy, 1045
Intracranial benign lesions, 749
Intracranial ependymoma, 825
Intracranial tumors, 591
Intraluminal brachytherapy, 1133
Intraluminal, 1241
Intraoperative radiation therapy, 1145
Intraoperative radiotherapy, 501
Intraoperative, 1241
Invasive ductal breast carcinoma, 423
Iodine radioisotopes, 1541
Iodine-125, 601
Iodine-125 implantation, 537
Iodine-131, 1601
Ionizing radiation, 1457
Iridium-192, 1173
Irradiation, 109, 885, 989, 1221
Adjuvant, 1019
Concomitant with chemotherapy, 1269
Definitive breast, 279
Fractionated, 749, 1231
Hepatic, 1151
Interstitial, 1485
Intracavitary, 995
Low dose rate, 975, 1523
Low-dose-rate, 397
Pelvic, 1157
Postoperative, 319, 767
Preoperative, 379, 1127
Prophylactic spinal, 825
Scalp, 1063
Thoracic, 459, 1269
Total body, 1167, 1587
Whole abdominal, 1013
Whole abdomino-pelvic, 1019
Irradical surgery, 1297

K

Kasabach-Merritt syndrome, 729
Kidney, 229
KU-2285, 1231

L

L-Q model, 1275, 1529
Large bowel, 229
Large breasts, 347
Laryngeal carcinoma, 767
Laryngeal neoplasms, 1607
Larynx carcinoma, 183
Larynx, 1315
Laser, 441
Late effects, 1187
Late sequelae, 447
Late, 1523
LDR brachytherapy, 1425
Least-squares optimization, 483
Limb function, 1493
Limb salvage, 1221
Linear accelerator, 737
Linear accelerators, 501
Linear quadratic model, 1373
Liver cancer, 463
Liver, Neoplasms, 1601
Local control and survival, 1385
Local control, 459, 537, 805
Local recurrence, 293, 293, 941
Local-regional control, 549
Local
Control, 537
Relapse, 537
Locoregional control 1179
Locoregionally advanced breast cancer,319
Logistic model, 591
Logistic regression, 813
Long term risk, 361
Low dose rate irradiation, 975, 1523
Low dose rate, 1415
Low grade, 1167
Low-dose-rate irradiation, 397
Lumpectomy, 279
Lung cancer, 217, 645, 1275
Apical, 651
Non-small cell, 779
Recurrent, 645
Small cell, 459, 645
Small-cell, 1269
Lung dose, 1257
Lung, 369
Cancer 779
Neoplasms, 637, 651
Non-small cell carcinoma, 629
Lymphoid precursor cell, 1553

M

Malignancies, Superficial, 1627
Malignant glioma, 601, 715
Malignant gliomas, 709
Mammalian cells, 1457
Mammary carcinoma, 1569
Mantle radiotherapy, 447
Mastectomy, 319
Mathematical model, 1587
Mathematical models ofdose-fractionation, 1441
Mediastinal involvement, 629
Medically inoperable, 375
Metabolism, 1235
Metastases, 537
Metastasis(es), 637
Distant, 549, 805
Occult neck, 577
Pulmonary, 1187
Microspheres, 463
Microwave, 403
Mini ovoids, 911
Minicolpostat, 1045
Misonidazole, 675
Mitomycin C, 1115, 1291, 1385, 1523
Model(s)
Generalized linear, 813
Normal tissue complicationprobability, 757
Tumor control probability, 757
Model
L-Q, 1275, 1529
Linear quadratic, 1373
Mathematical, 1587
Radiobiologic, 1373
Modelling, Thermal, 431
Morbidity, 935
Mouse bladder, 1211
Mouse tumor, 1561
MR imaging, 1089
MRI, 1643
Multimodality imaging, 1653
Multivariate analysis, 549
Murine ovarian tumor, 1541
Musculoskeletal tumors, 1643
Myelitis, 1373
Myocardial infarction, 447

N

1988 FIGO revisions, 1027
Nasopharyngeal carcinoma, 723
Nasopharynx, 169
Neck recurrence, 577
Neoplasm(s)
Biliary tract, 1601
Bone, 1509
Cervix, 899
Larngeal, 1607
Liver, 1601
Lung, 637, 651
Second malignant, 583, 1187
Superior sulcus, 651
Neoplasm, Brain, 715
Neurofibromatosis, 615
New design, 511
NHL, 1167
Nitroimidazoles, 387
Nodes, Para-aortic, 229
Nominal standard dose, 1373
Non-small cell carcinoma, Lung, 629
Non-small cell lung cancer, 779
Normal tissue complication probabilitymodels, 757
Normal tissue complication probability,3, 147
Normal tissue tolerance, 229
Normal tissue, 1561
Tolerance, 109
Number of heat treatments, 1569
Numerical scoring, 147

O

137-CS, 1053
Occult neck metastases, 577
On-line radiotherapy imaging, 1327
Optimization in radiotherapy, 779
Optimization, 147, 1247, 1575, 1587,1621
Orbital radiotherapy, 795
Oropharynx carcinoma, 557
Ototoxic effects, 723
Outcome, 1085
Output factor, 789
Ovarian cancer, 1013
Overall time, 813

P

Pancoast tumor, 651
Pancreas cancer, 451

Pancreas, Adenocarcinoma, 1137
Pancreatectomy, 1137
Pancreatic cancer, 1145
Para-aortic nodes, 229
Parameters, 123
Particle radiotherapy, 1005
Pathology margins, 279
Patient immobilization, 757
Patterns of Care, 1085
PCV chemotherapy, 709
Pelvic irradiation, 1157
Pelvic, Recurrence, 1157
Pericarditis, 447
Pharmacolig erection, 1311
Phosphomnoester, 667
Photon beam analysis, 91
Photon(s), 193
Photosensitizer, 441
Pig skin, 1441
Pions, 1005
Pituitary adenoma, 607
Pituitary cancer, 1311
Plan evaluation, 147
Planning
  CT-based implant, 483
  Three-dimensional, 169, 229, 1575
  Treatment, 169, 193, 217, 243, 431,1321, 1653
Plaque, 625
Plastic applicator, 1045
Post-mastectomy local regionalrecurrence, 299
Postoperative irradiation, 319, 767
Postoperative radiotherapy, 949, 1297,1595
Potentially lethal damage, 1457
Precise positioning, 757
Preoperative irradiation, 379, 1127
Preoperative radiotherapy, 325, 1595
Primary culture, 661
Probability
  Normal tissue complication, 3
  Normal tissue complicationm, 147
  Tumor control, 3, 147, 1471
Procedure, Whipple, 1137
Prognosis, 293
Prognostic factors, 299, 629, 1179
Prognostic variables, 905
Prolongation, 813
Prone positioning, 1303
Prophylactic spinal irradiation, 825
Prostaglandin, 1311
Prostate cancer, 243
Prostate implant, 483
Prostate, 1200
  Cancer 935
  Cancer, 941, 949, 1099, 1311
  Carcinoma, 537, 925, 955
Protection, Radiation, 1479
Proton therapy, 757
Pulmonary effects, 355
Pulmonary metastases, 1187
Pulsed treatment, 1403

Q

Quality assurance, 737
Quamtitative histology, 989
Quantitative autoradiography, 1635

R

Radiation 629
Radiation dose, 1471
Radiation reaction, Acute and late, 1441
Radiation sensitivity, 1553
Radiation therapy, 9, 71, 79, 193, 217,243, 269, 311, 347, 355, 637,645, 651, 805, 885, 905, 911,919, 935, 961, 1041, 1089, 1099,1145, 1275, 1283, 1501, 1607
  Computer-controlled, 1247
  Dose, 1501
  External beam, 961
  Interstitial, 451, 961
  Intraoperative, 1145
Radiation treatment planning, Three-dimensional, 491
Radiation, 289, 1115
Radiation-induced human sarcomas, 1677
Radiation-induced sarcoma, 361
Radiation
  Complications, 1471
  Damage, 1211
  Dose, 1471
  Fractionation, 1377
  Injuries, 1373
  Ionizing, 1457
  Pneumonitis, 355
  Protection, 1479
  Sensitivity, 1553
  Sensitization, 969
  Sensitizers, 969
  Survey, 1057
  Volume, 1501
Radiaton therapy, Chemosensitized, 1137
Radio pill, 1353
Radiobiologic model, 1373
Radiobiology, 1587
Radioimmunoglobulin therapy, 1627
Radioimmunotherapy, 1601
Radioiodo-estradiol, 1235
Radioprotection, 1241
Radioresistance, 1203
Radiosensitization, 387
Radiosensitizer, 983
  Hypoxic cell, 1231
Radiosensitizers, Combined, 1535
Radiosurgery, 749, 819, 1321
  Stereotactic, 491, 591, 683, 737, 1247
Radiotherapy, 123, 299, 339, 415, 469,537, 557, 563, 577, 607, 615,703, 723, 729, 899, 925, 1133,1157, 1179, 1241, 1291, 1315,1321, 1363, 1509, 1517, 1541
  Accelerated hyperfractionation, 569
  Biologically targeted, 1587
  Conformational, 1575
  definitive, 1173
  Intraoperative, 501
  Mantle, 447
  Optimization, 779
  Orbital, 795
  Particle, 1005
  Postoperative, 949, 1297, 1595
  Preoperative, 325, 1595
  Stereotactic, 819
  Thoracic, 1257
  Three-dimensional, 205
  Whole lung, 1187
Radium (substitutes), 1479
Radomized trial, 415
Rate
  Dose, 1403
  High dose, 1415
  Low dose, 1415
Ratio
  Alpha/beta, 1529
  Thermal enhancement, 1561
Ray tracing, 491
Reconstruction, 339
Rectal cancer, 1337
Rectal carcinoma, 253, 1127
Rectum and/or sigmoid cancer, 1297
Recurrence
  Breast, 269
  Local, 293, 293, 941
  Neck, 577
  Pelvic, 1157
  Post-mastectomy local regional, 299
Recurrent lung cancer, 645
Recurrent rectal carcinoma, 1291
Recurrent, 625
Remodeling, 1221
Remote afterloading, 1425
Renal shielding, 1363
Repair, 675, 1457
  DNA, 983
  Sublethal damage, 983
Repopulation, 675, 1195, 1377, 1529
  Accelerated, 1529
Results, Cosmetic, 347
Retinoblastoma, 625
Revisions, 1988 FIGO, 1027
Rib fractures, 1373
Ring applicator, 1621
Risk, Long term, 361
Ro 3-8799, 1535
RTOG, 549

S

Salivary gland tumors, 569
SAR, 403
Sarcoma(s)
  Radiation-induced human, 1677
  Radiation-induced, 361
Sarcoma
  Epidemic Kaposi's, 1517
  Ewing's, 1501, 1509
  Soft tissue, 1485, 1493, 1595
Scalp irradiation, 1063
Scatter ray-trace, 59
Scitigraphy, 1541
Scoring, 137
  Numerical, 147
Second malignant neoplasms, 583, 1187
Secondary tumorectomy, 325
Sensitization, Radiation, 969
Sensitizers, Radiation, 969
Sensori-neural hearing loss, 723
Sequelae, Late, 447
Sesitivity, Radiation, 1553
Set-up techniques, 1073
Shielding
  Internal, 1337
  Renal, 1363
Simulation, 475
  Virtual, 475
Skin, 1523
Small bowel, 229
Small cell lung cancer, 459, 645
Small-cell lung cancer, 1269
Soft tissue sarcoma, 1595
Soft tissue
  Sarcoma, 1485, 1493
Soft tissues, 1523
Source calibration, 1057
Spin-lattice relaxation, 667
Spinal cord, 229
Spinal seeding, 825
Split-course, 1013
Spontaneous cancer, 415
Squamous cell carcinoma, 563, 661
  Oral tongue, 577
SR-2508, 1535
Stage II, 1027

Stage III, 311
Standard cesium tube, 511
Stereotactic brachytherapy, 715
Stereotactic radiosrgery, 591
Stereotactic radiosurgery, 491, 683,737, 1247
Stereotactic radiotherapy, 819
Stereotactic, 1321
Stereotaxy, 601, 749
Stromal cell, 1203
Structure, Facility, 1085
Subglottic carcinoma, 1607
Sublethal damage repair, 983
Sublethal damage, 1457
Superficial malignancies, 1627
Superior sulcus neoplasms, 651
Surface dose, 1627
Surgery, 629, 899
  Conservative, 293, 355
  Irradical, 1297
Survival, 1179
Syndrome, Kasabach-Merritt, 729
Systems, Dosimetry, 1479

T

31-P NMR, 667
Tangential fields, 1073
Target absorbed dose, 1257
Techniques, Set-up, 1073
Temperature distribution, 423
Template, 483
Therapeutic gain factor, 1561
Therapy
  Adjuvant, 1137
  Arc, 749
  Breast conservation, 289
  Chemo-radiation, 1385
  Combination, 1151
  Combined modality, 899, 1493
  Interstitial, 1479
  Intracavitary, 1045
  Proton, 757
  Radiation, 9, 71, 79, 193, 217, 243,269, 311, 347, 355, 637, 645,651, 805, 885, 905, 911, 919,935, 961, 1041, 1089, 1099, 1145,1275, 1283, 1501, 1607
  Radioimmunoglobulin, 1627
Theraty, Electron arc, 515
Thermal enhancement ratio, 1561
Thermal modelling, 431
Thermoluminescent dosimetry, 1337
Thermometry, 1353
Thoracic irradiation, 459, 1269
Thoracic radiotherapy, 1257
Three-dimensional display, 9
Three-dimensional planning, 169, 1575
Three-dimensional treatment planning,9, 1303
Three-dimensional, 217, 243, 805
  Display, 9, 79
  Dose distributions, 767
  Planning, 169, 229, 1575
  Radiation treatment planning, 491
  Radiotherapy, 205
  Treatment design, 475
  Treatment planning, 3, 9, 25, 59, 79,91, 109, 147, 183, 253, 475, 683
Three-dimensional? Treatment planning,137
Time factor, 1451
Time-dose-fractionation, 925
Tissue heterogeneity, 1613
Tissue inhomogeneity corrections, 183
Tissue tolerance(s), 123
Tissue
  Inhomogeneity corrections, 183
  Normal, 1561
  Tolerance(s), 123
Tissues, Soft, 1523
Tolerance(s)
  Normal tissue, 229
  Tissue, 123
Tolerance, Normal tissue, 109
Tomography, Computed, 193
Total body irradiation (TBI), 1167
Total body irradiation, 1587
Transperineal implants, 483
Treatment design, Three-dimensional, 475
Treatment effects, 1493
Treatment planning, 3, 123, 169, 193,217, 243, 431, 1321
  Comparative, 757
  Computerized, 71
  Evaluation, 137
  External photon, 37
  Three dimensional, 3
  Three-dimensional, 9, 25, 59, 79, 91,109, 137, 147, 183, 253, 475,683, 1303
Treatment, 955
  Combined modality, 1509
  Complications, 1157
  Effects, 1493
  Planning, 1653
  Pulsed, 1403
  Verification, 1327
  Volume, 1005
Trial, Randomized, 415
Tumor bed effect, 667
Tumor control probability models, 757
Tumor control probability, 3, 1471
Tumor oxygenation, 667
Tumor staging, 1643
Tumor(s) , Staging, 1643
Tumor(s), 1195
  Bone, 1221
  Brain 819
  FSa-II, 1529
  Intracranial, 591
  Mouse, 1561
  Musculoskeletal, 1643
  Pancoast, 651
  Salivary gland, 569
  Wilms', 1187
Tumor
  Bed effect, 1435
  Control probability, 3, 147, 1471
  Control, 885
  Hypoxia, 969, 1435
Tumorectomy, Secondary, 325
Tumro(s), Murine ovarian, 1541
Twice-daily fractionation, 1013

U

Ultrasound, 831, 1363
Uncertainty analysis, 91
Unresectable head and neck cancer, 703
Unresectable rectal cancer, 1283
Upper esophageal manometry, 1315
Uterine cancers, 995
Uterine cervical cancer, 905
Uterine cervix, 885
Uterine-vaginal applicator, 511

V

-V malformation, 749
V-abl oncogene, 1203
Vaginal carcinoma, 1041
Vaginal, 1053
Variables, Prognostic, 905
Vascular density, 423
Virtual simulation, 475
Visualization, 683
Volume effects, 109
Volume rendering, 491
Volume
  Delta, 59
  Radiation, 1501
  Treatment, 1005

W

Whipple procedure, 1137
Whole abdominal irradiation, 1013
Whole abdomino-pelvic irradiation, 1019
Whole lung radiotherapy, 1187
Wilms' tumor, 1187
WR-2721, 1241

X

X-ray-mediated gene expression, 1677
Xenograft, Human melanoma, 989
Xenografts, Human tumor, 1535

Y

Yttrium-90, 463